Colon Cancer Prevention and Control
Colorectal cancer is the third-most common malignancy in the United States and the second-leading cause of cancer-related mortality.
Although screening is universally recommended in the United States, screening rates are low nationally and among racial and ethnic minorities.
The May Laboratory works with collaborators in public health, informatics, general internal medicine, and biostatistics to design and implement interventions to increase uptake of colorectal cancer screening and to improve completion of diagnostic follow-up when screening is abnormal.
Research in this area also includes analyses utilizing publicly available national- and state-level databases to evaluate screening rates and cancer outcomes.
The portfolio of work encompass both health disparities research and health systems quality improvement research, but goes beyond.
- Roshan Bastani, PhD, Professor, Health Policy and Management
- Beth Glenn, PhD, Associate Professor, Health Policy and Management
- Allison Hermann, PhD, Associate Director, Center for Health Equity, Health Equity
- Exact Sciences; “A Longitudinal Study of CologuardTM in an Average Risk Population Assessing a Three Year Test Interval” (site PI)
- UCLA Jonsson Cancer Center Foundation Seed Grant; “A Community-Academic Partnership to Improve Colorectal Cancer Screening in South Los Angeles” (PI)
- Charles Drew University-UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities Seed Grant; “A Community Partnership to Improve Follow-up After Positive Colorectal Cancer Screening” (PI)
- National Cancer Institute: “Follow-up of Abnormal Findings on Colorectal Cancer Screening in a Federally Qualified Health Center: The Role of System-Level Clinical Care Processes"
- May FP, Yang L, Corona E, Glenn BA, Bastani R. Disparities in Colorectal Cancer Screening in the United States Before and After Implementation of the Affordable Care Act. Clin Gastroenterol Hepatol. 2019 Sep 13;. doi: 10.1016/j.cgh.2019.09.008. [Epub ahead of print] PubMed PMID: 31525514
- Bharti B, May FFP, Nodora J, Martinez ME, Moyano K, Davis SL, Ramers CB, Garcia-Bigley F, O'Connell S, Ronan K, Barajas M, Gordon S, Diaz G, Ceja E, Powers M, Arredondo EM, Gupta S. Diagnostic colonoscopy completion after abnormal fecal immunochemical testing and quality of tests used at 8 Federally Qualified Health Centers in Southern California: Opportunities for improving screening outcomes.Cancer. 2019 Sep 3;. doi: 10.1002/cncr.32440. [Epub ahead of print] PubMed PMID: 31479529
- May FP, Yano EM, Provenzale D, Brunner J, Yu C, Phan J, Bharath P, Aby E, Dinh D, Ehrlich DS, Storage T, Lin LD, Jamaluddin NN, Washington DL. Barriers to Follow-up Colonoscopies for Patients with Positive Results from Fecal Immunochemical Tests During Colorectal Cancer Screening. Clin Gastroenterol Hepatol. 2018 May 29 pii: S1542-3565(18)30554-8. doi: 10.1016/j.cgh.2018.05.022. PMID: 29857147
- May FP, Yano EM, Provenzale D, Neil Steers W, Washington DL. The Association Between Primary Source of Healthcare Coverage and Colorectal Cancer Screening Among US Veterans. Dig Dis Sci. 2017 Aug;62(8):1923-1932
- May FP, Glen B, Crespi C, Spiegel B, Ponce N, Bastani R. Decreasing black-white disparities in colorectal cancer incidence and stage at presentation in the United States. Cancer Epidemiol Biomarkers Prev. 2016 Dec. 2017 May;26(5):762-768. PMID: 28035021
- May FP, Almario C, Ponce N, Spiegel BM. Racial minorities are more likely than whites to report lack of provider recommendation for colon cancer screening. Am J Gastroenterol. 2015 Oct;110(10):1388-94. doi: 10.1038/ajg.2015.138. Epub 2015 May 12
- May FP, Bromley EG, Baek M, Yoon J, Cohen E, Lee A, Reid MW, van Oijen MG, Spiegel BM. Low uptake of colorectal cancer screening among African-Americans in an integrated Veterans Affairs health care network. Gastrointest Endosc. 2014 Aug; 80(2):291-8. doi: 10.1016/j.gie.2014.01.045. Epub 2014 Mar 25. PMID: 24674351